Abstract
Despite continuing advances in the development of biomacromolecules for therapeutic purposes, successful application of these often large and hydrophilic molecules has been hindered by their inability to efficiently traverse the cellular plasma membrane. In recent years, cell-penetrating peptides (CPPs) have received considerable attention as a promising class of delivery vectors due to their ability to mediate the efficient import of a large number of cargoes in vitro and in vivo. However, the lack of target specificity of CPPs remains a major obstacle to their clinical development. To address this issue, researchers have developed strategies in which chemotherapeutic drugs are conjugated to cancer targeting peptides (CTPs) that exploit the unique characteristics of the tumor microenvironment or cancer cells, thereby improving cancer cell specificity. This review highlights several of these strategies that are currently in use, and discusses how multi-component nanoparticles conjugated to CTPs can be designed to provide a more efficient cancer therapeutic delivery strategy.
Similar content being viewed by others
References
Juliano R (2007) Challenges to macromolecular drug delivery. Portland Press Limited, London
Bolhassani A (2011) Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta (BBA) Rev Cancer 1816(2):232–246
McErlean EM, McCrudden CM, McCarthy HO (2015) Multifunctional delivery systems for cancer gene therapy. In: Hashad D (ed) Gene therapy—principles and challenges. InTech, London
Regberg J, Srimanee A, Langel Ü (2012) Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals 5(9):991–1007
Magzoub M, Gräslund A (2004) Cell-penetrating peptides: small from inception to application. Q Rev Biophys 37(2):147–195
Reissmann S (2014) Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci 20(10):760–784
Derossi D et al (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269(14):10444–10450
Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272(25):16010–16017
Zorko M, Langel Ü (2005) Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57(4):529–545
Snyder EL, Dowdy SF (2004) Cell penetrating peptides in drug delivery. Pharm Res 21(3):389–393
Schwarze SR et al (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285(5433):1569–1572
Josephson L et al (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 10(2):186–191
Jiang Q-Y et al (2011) Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine. Biomaterials 32(29):7253–7262
Asai T et al (2014) Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem Biophys Res Commun 444(4):599–604
Lehto T, Kurrikoff K, Langel Ü (2012) Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 9(7):823–836
Juliano RL et al (2009) Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3):324–335
Bechara C, Sagan S (2013) Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 587(12):1693–1702
Raucher D, Ryu JS (2015) Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med 21(9):560–570
Foged C, Nielsen HM (2008) Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 5(1):105–117
Subrizi A et al (2012) Tat (48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cell-surface glycosaminoglycans inhibit its cellular uptake. J Control Release 158(2):277–285
Åmand HL et al (2008) Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem Biophys Res Commun 371(4):621–625
Mitchell DJ et al (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56(5):318–325
Kalafatovic D, Giralt E (2017) Cell-penetrating peptides: design strategies beyond primary structure and amphipathicity. Molecules 22(11):1929
Franz J et al (2016) SAP (E)—a cell-penetrating polyproline helix at lipid interfaces. Biochim Biophys Acta (BBA) Biomembr 1858(9):2028–2034
Kristensen M, Birch D, Mørck Nielsen H (2016) Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int J Mol Sci 17(2):185
Rydberg HA et al (2012) Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides. Biochemistry 51(27):5531–5539
Borrelli A et al (2018) Cell penetrating peptides as molecular carriers for anti-cancer agents. Molecules 23(2):295
Rydström A et al (2011) Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One 6(10):e25924
Guo Z et al (2016) Cell-penetrating peptides: possible transduction mechanisms and therapeutic applications. Biomed Rep 4(5):528–534
Simeoni F et al (2003) Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31(11):2717–2724
Copolovici DM et al (2014) Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8(3):1972–1994
Avci F, Sariyar Akbulut B, Ozkirimli E (2018) Membrane active peptides and their biophysical characterization. Biomolecules 8(3):77
Mussbach F et al (2011) Transduction of peptides and proteins into live cells by cell penetrating peptides. J Cell Biochem 112(12):3824–3833
Brock R (2014) The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug Chem 25(5):863–868
Vivès E, Schmidt J, Pèlegrin A (2008) Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta (BBA) Rev Cancer 1786(2):126–138
LeCher JC, Nowak SJ, McMurry JL (2017) Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem. Biomol Concepts 8(3–4):131–141
Jiang T et al (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101(51):17867–17872
Huang S et al (2013) Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 34(21):5294–5302
Jiang B (2017) Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment. Genes Dis 4(1):25–27
Nguyen VP et al (2015) A novel soluble peptide with pH-responsive membrane insertion. Biochemistry 54(43):6567–6575
Gao W, Chan JM, Farokhzad OC (2010) pH-responsive nanoparticles for drug delivery. Mol Pharm 7(6):1913–1920
Daumar P et al (2012) Efficient 18F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjug Chem 23(8):1557–1566
Reshetnyak YK et al (2011) Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP. Mol Imaging Biol 13(6):1146–1156
Vāvere AL et al (2009) A novel technology for the imaging of acidic prostate tumors by positron emission tomography. Can Res 69(10):4510–4516
Karabadzhak AG et al (2014) pHLIP-FIRE, a cell insertion-triggered fluorescent probe for imaging tumors demonstrates targeted cargo delivery in vivo. ACS Chem Biol 9(11):2545–2553
An M et al (2010) pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation. Proc Natl Acad Sci 107(47):20246–20250
Moshnikova A et al (2013) Antiproliferative effect of pHLIP-amanitin. Biochemistry 52(7):1171–1178
Reshetnyak YK et al (2006) Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci 103(17):6460–6465
Hunt JF et al (1997) Spontaneous, pH-dependent membrane insertion of a transbilayer α-helix. Biochemistry 36(49):15177–15192
Andreev OA, Engelman DM, Reshetnyak YK (2014) Targeting diseased tissues by pHLIP insertion at low cell surface pH. Front Physiol 5:1–7
Yao L et al (2013) pHLIP peptide targets nanogold particles to tumors. Proc Natl Acad Sci 110(2):465–470
Andreev OA, Engelman DM, Reshetnyak YK (2009) Targeting acidic diseased tissue: new technology based on use of the pH (Low) Insertion Peptide (pHLIP). Chim Oggi 27(2):34
Andreev OA, Engelman DM, Reshetnyak YK (2010) pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol Membr Biol 27(7):341–352
Deacon JC, Engelman DM, Barrera FN (2015) Targeting acidity in diseased tissues: mechanism and applications of the membrane-inserting peptide, pHLIP. Arch Biochem Biophys 565:40–48
Zoonens M, Reshetnyak YK, Engelman DM (2008) Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors. Biophys J 95(1):225–235
Wei Y et al (2017) pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent. Acta Biomater 55:194–203
Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM (2017) Applications of pHLIP technology for cancer imaging and therapy. Trends Biotechnol 35(7):653–664
Weerakkody D et al (2013) Family of pH (low) insertion peptides for tumor targeting. Proc Natl Acad Sci 110(15):5834–5839
Reshetnyak YK et al (2008) Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane. Proc Natl Acad Sci 105(40):15340–15345
Wijesinghe D et al (2013) pH dependent transfer of nano-pores into membrane of cancer cells to induce apoptosis. Sci Rep 3:3560
Song Q et al (2016) A smart tumor targeting peptide–drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells. Drug Deliv 23(5):1734–1746
Kyrychenko A (2015) NANOGOLD decorated by pHLIP peptide: comparative force field study. Phys Chem Chem Phys 17(19):12648–12660
Anderson MD (2015) Development of new tools for study of tumor microenvironment. Open access Dissertations. Paper 359
Demoin DW et al (2016) PET imaging of extracellular pH in tumors with 64Cu-and 18F-labeled pHLIP peptides: a structure–activity optimization study. Bioconjug Chem 27(9):2014–2023
Andreev OA et al (2010) pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path. Proc Natl Acad Sci 107(9):4081–4086
Karabadzhak AG et al (2012) Modulation of the pHLIP transmembrane helix insertion pathway. Biophys J 102(8):1846–1855
Shu NS et al (2015) Residue-specific structures and membrane locations of pH-low insertion peptide by solid-state nuclear magnetic resonance. Nat Commun 6:1–10
Hanz SZ et al (2016) Protonation-driven membrane insertion of a pH-low insertion peptide. Angew Chem Int Ed 55(40):12376–12381
Narayanan T et al (2016) pHLIP peptide interaction with a membrane monitored by SAXS. J Phys Chem B 120(44):11484–11491
Daniels JL et al (2017) Synthesis and characterization of pHLIP® coated gold nanoparticles. Biochem Biophys Rep 10:62–69
Scott HL et al (2015) The negative charge of the membrane has opposite effects on the membrane entry and exit of pH-low insertion peptide. Biochemistry 54(9):1709–1712
Gupta C, Mertz B (2017) Protonation Enhances the Inherent Helix-Forming Propensity of pHLIP. ACS Omega 2(11):8536–8542
Sosunov EA et al (2013) pH (low) insertion peptide (pHLIP) targets ischemic myocardium. Proc Natl Acad Sci 110(1):82–86
Van Meer G, Voelker DR, Feigenson GW (2008) Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 9(2):112–124
Vasquez-Montes V et al (2018) Comparison of lipid-dependent bilayer insertion of pHLIP and its P20G variant. Biochim Biophys Acta (BBA) Biomembr 1860(2):534–543
Kyrychenko A et al (2015) Lipid headgroups modulate membrane insertion of pHLIP peptide. Biophys J 108(4):791–794
Wyatt LC et al (2018) Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors. Proc Natl Acad Sci 115(12):E2811–E2818
Petrova V et al (2018) The hypoxic tumour microenvironment. Oncogenesis 7(1):10
Kim Y et al (2009) Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 9(4):425–434
Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40(2):294–309
Harada H, Hiraoka M, Kizaka-Kondoh S (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Can Res 62(7):2013–2018
Nalla AK et al (2010) Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther 17(9):599
Polette M et al (2004) Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 49(3):179–186
Weidle UH, Tiefenthaler G, Georges G (2014) Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genom Proteom 11(2):67–79
Olson ES et al (2009) In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol 1(5–6):382–393
Hofmann H-S et al (2005) Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 11(3):1086–1092
Gong Y, Chippada-Venkata UD, Oh WK (2014) Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers 6(3):1298–1327
van Duijnhoven SM et al (2011) Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med 52(2):279–286
Aguilera TA et al (2009) Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol 1(5–6):371–381
Anderson CF, Cui H (2017) Protease-sensitive nanomaterials for cancer therapeutics and imaging. Ind Eng Chem Res 56(20):5761–5777
Shi N-Q et al (2012) Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int J Nanomed 7:1613
Jiang T et al (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci 101(51):17867–17872
Nguyen QT et al (2010) Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci 107(9):4317–4322
Malhotra M et al (2013) Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomed 8:2041
Lee SH et al (2014) Activatable cell penetrating peptide–peptide nucleic acid conjugate via reduction of azobenzene PEG chains. J Am Chem Soc 136(37):12868–12871
Wender PA et al (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci 97(24):13003–13008
Jin E et al (2013) Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J Am Chem Soc 135(2):933–940
Bode SA et al (2015) Enzyme-activatable cell-penetrating peptides through a minimal side chain modification. Bioconjug Chem 26(5):850–856
Vocero-Akbani AM et al (1999) Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 5(1):29
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033
Mathupala S, Ko YA, Pedersen P (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777–4786
Arzoine L et al (2009) Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol Chem 284(6):3946–3955
Woldetsadik AD et al (2017) Hexokinase II–derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. FASEB J 31(5):2168–2184
Pastorino JG, Shulga N, Hoek JB (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277(9):7610–7618
Patra KC et al (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24(2):213–228
Rezgui R et al (2016) Precise quantification of cellular uptake of cell-penetrating peptides using fluorescence-activated cell sorting and fluorescence correlation spectroscopy. Biochim Biophys Acta (BBA) Biomembr 1858(7):1499–1506
Takayama K et al (2012) Effect of the attachment of a penetration accelerating sequence and the influence of hydrophobicity on octaarginine-mediated intracellular delivery. Mol Pharm 9(5):1222–1230
Kondo E et al (2012) Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun 3:951
Shi J et al (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20
Zuo HD et al (2014) The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study. BioMed Res Int 2014:1–8
Shirazi AN et al (2014) Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. Molecules 19(9):13319–13331
Li H, Tsui T, Ma W (2015) Intracellular delivery of molecular cargo using cell-penetrating peptides and the combination strategies. Int J Mol Sci 16(8):19518–19536
Qin H et al (2017) Tumor microenvironment targeting and responsive peptide-based nanoformulations for improved tumor therapy. Mol Pharmacol. 1:1. https://doi.org/10.1124/mol.116.108084
Yoo J et al (2017) Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy. J Control Release 264:89–101
Acknowledgements
The authors thank Professor David Male (The Open University) for critical reading of the manuscript. This work was supported by funding from NYU Abu Dhabi (Research Grant) and an ADEK Award for Research Excellence Grant (AARE17-089) to M.M.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing financial interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kalmouni, M., Al-Hosani, S. & Magzoub, M. Cancer targeting peptides. Cell. Mol. Life Sci. 76, 2171–2183 (2019). https://doi.org/10.1007/s00018-019-03061-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-019-03061-0